Global /United States /Healthcare /Drug Manufacturers - General /AEON

AEON Biopharma, Inc.

AEON

• NYSEAMERICAN: AEON • Delayed

0.9547USD -3%

As of 13 June 2026, AEON Biopharma, Inc. has a market cap of $24.16M USD, ranking #35752 globally and #4895 in the United States. It ranks #3217 in the Healthcare sector, and #1084 in the Drug Manufacturers - General industry.

Global Rank

35752

Country Rank

4895

Sector Rank

3217

Industry Rank

1084

Key Stats

Market Cap

$24.16MUSD

Enterprise Value

$57.66MUSD

EBITDA (TTM)

-$16.22MUSD

Net Income (TTM)

-$39.22MUSD

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert Bancroft open_in_new

Employees

Website

aeonbiopharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3%	-12%	-18%	-19%	2.7%	-13%	127%	-100%	-100%

News

AEON Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE American (NYSEAMERICAN / AMEX) MIC: XASE PRIMARY	AEON AEON Biopharma Inc Ordinary Shares - Class A ISIN: US00791X2099 Shares Out.: Shares Outstanding: 26.307M¹ Shares Float: 8.643M² TV: TradingView: AMEX: AEON SA: Stock Analysis: NYSEAMERICAN: AEON YF: Yahoo Finance: AEON GF: Google Finance: NYSEAMERICAN: AEON NQ: NASDAQ: AEON BA: Barron's: AEON MS: Morningstar: XASE: AEON	0.9547 USD	TV: TradingView: AMEX: AEON SA: Stock Analysis: NYSEAMERICAN: AEON YF: Yahoo Finance: AEON GF: Google Finance: NYSEAMERICAN: AEON NQ: NASDAQ: AEON BA: Barron's: AEON MS: Morningstar: XASE: AEON

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 2M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 1M%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 1M%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 618K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 487K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 1M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 1M%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 753K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 456K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 449K%	14.6	United Kingdom

chevron_leftBack